Literature DB >> 1059501

Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study.

W W Sutow, M P Sullivan, D J Fernbach, A Cangir, S L George.   

Abstract

A four-drug adjuvant chemotherapy regimen (CONPADRI-I) was utilized in the primary treatment of 18 children with osteogenic sarcoma. All patients had surgical amputation for the primary lesion. The children then received cyclophosphamide, vincristine, melphalan, and adriamycin in defined combinations intermittently over a 72-week period. Of the 18 patients, 10 (55%) remain free of disease 24 months or longer from time of amputation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1059501     DOI: 10.1002/1097-0142(197511)36:5<1598::aid-cncr2820360511>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Radiotherapy and chemotherapy of limb tumours.

Authors:  D Pearson
Journal:  Ann R Coll Surg Engl       Date:  1980-03       Impact factor: 1.891

2.  Adjuvant systemic therapy after ablative surgery for limb osteosarcoma.

Authors:  B M Cantwell; J J Fennelly; M P Jones
Journal:  Ir J Med Sci       Date:  1982-12       Impact factor: 1.568

Review 3.  Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

Authors:  Robert S Benjamin
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Risk-Based Therapy for Localized Osteosarcoma.

Authors:  Rajkumar Venkatramani; Jeffrey Murray; Lee Helman; William Meyer; M John Hicks; Robert Krance; Ching Lau; Eunji Jo; Murali Chintagumpala
Journal:  Pediatr Blood Cancer       Date:  2015-10-26       Impact factor: 3.167

5.  The Current and Future Therapies for Human Osteosarcoma.

Authors:  Joseph D Lamplot; Sahitya Denduluri; Jiaqiang Qin; Ruidong Li; Xing Liu; Hongyu Zhang; Xiang Chen; Ning Wang; Abdullah Pratt; Wei Shui; Xiaoji Luo; Guoxin Nan; Zhong-Liang Deng; Jinyong Luo; Rex C Haydon; Tong-Chuan He; Hue H Luu
Journal:  Curr Cancer Ther Rev       Date:  2013-02

Review 6.  Update on Osteosarcoma.

Authors:  Rebekah Belayneh; Mitchell S Fourman; Sumail Bhogal; Kurt R Weiss
Journal:  Curr Oncol Rep       Date:  2021-04-21       Impact factor: 5.075

7.  Vascular endothelial growth factor polymorphisms are associated with osteosarcoma susceptibility.

Authors:  Yuan-Yuan Hu; Xin-Ya Du; Ai-Ling Zhan; Lan Zhou; Qian Jiang; Yu-Ming Niu; Ming Shen
Journal:  Oncotarget       Date:  2016-07-26

8.  Osteosarcoma: a comprehensive review.

Authors:  Amirhossein Misaghi; Amanda Goldin; Moayd Awad; Anna A Kulidjian
Journal:  SICOT J       Date:  2018-04-09

Review 9.  The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.

Authors:  Bin Zhang; Yan Zhang; Rongzhen Li; Jiazhen Li; Xinchang Lu; Yi Zhang
Journal:  J Orthop Surg Res       Date:  2020-02-13       Impact factor: 2.359

10.  Osteosarcoma: evolution of treatment paradigms.

Authors:  Norman Jaffe; Ajay Puri; Hans Gelderblom
Journal:  Sarcoma       Date:  2013-05-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.